Novastan (Argatroban Monohydrate)

Argatroban, the active ingredient in Novastan, is a direct thrombin inhibitor presented as an intravenous solution for intravenous use. It treats patients with heparin‑induced thrombocytopenia, supports anticoagulation during percutaneous coronary intervention, and prevents thrombosis when heparin is contraindicated.

GNH USA supplies Novastan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Novastan (argatroban) is used in clinical settings that require direct thrombin inhibition to manage coagulation disorders.

Heparin‑induced thrombocytopenia (HIT): provides anticoagulation without cross‑reactivity to heparin, reducing platelet activation. Percutaneous coronary intervention (PCI): maintains procedural anticoagulation to prevent clot formation during catheter‑based coronary procedures. Thrombosis prevention in heparin‑contraindicated patients: offers an alternative anticoagulant to reduce risk of thrombotic events when heparin cannot be used.

Argatroban may be associated with several adverse reactions, ranging from frequent, mild events to rare, serious conditions.

Common Side Effects: - Bleeding: mild to moderate hemorrhage at infusion sites, gums, or mucosal surfaces, often manageable with local measures. - Thrombocytopenia: a decrease in platelet count that may require monitoring and dose adjustment. - Nausea: occasional gastrointestinal discomfort or queasiness during infusion.

Serious or Rare Side Effects: - Severe bleeding: life‑threatening hemorrhage such as intracranial or gastrointestinal bleeding requiring urgent medical intervention. - Hepatic dysfunction: significant elevation of liver transaminases (ALT/AST) indicating possible liver injury, necessitating laboratory monitoring. - Allergic reactions: anaphylaxis or severe hypersensitivity manifesting as rash, bronchospasm, or hypotension.

When using Argatroban, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Dose adjustment: reduce dose in patients with hepatic impairment due to metabolism reliance. - Monitoring: regularly assess activated partial thromboplastin time (aPTT) to maintain therapeutic range. - Bleeding risk: evaluate for active bleeding or recent surgery before initiating therapy. - Drug interactions: avoid concurrent use with other anticoagulants unless closely supervised. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Argatroban can interact with several medicines, affecting anticoagulant effect or increasing toxicity.

Major Interactions (Avoid): - Other anticoagulants: concurrent use with warfarin, direct oral anticoagulants, or heparin may cause uncontrolled bleeding. - Strong CYP3A4 inhibitors: agents such as ketoconazole markedly increase argatroban plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: drugs like rifampin may reduce argatroban effectiveness. - Antiplatelet agents: aspirin or clopidogrel can enhance bleeding tendency. - NSAIDs: non‑steroidal anti‑inflammatory drugs may increase risk of hemorrhage.